Mitch Bloom > Goodwin > Boston, United States > Lawyer Profile

Goodwin provides a full-service offering to emerging companies and venture capital companies, supporting clients from initial seed financing stages through to exit transactions. The life sciences practice is co-chaired by Mitch Bloom and Kingsley Taft from Boston, and the technology and emerging companies team is jointly led by Kenneth Gordon in Boston and Craig Schmitz in New York. Bill Schnoor, based in Boston, specializes in business and securities law, private equity work, and acquisitions. Danielle Lauzon, who focuses on life sciences and healthcare information technology services clients, and William Collins, who is experienced in formations, capital markets transactions and exit strategies, bolster the Boston team. In Silicon Valley, Caine Moss assists companies in the software, AI, internet, and financial services sectors.

With a raft of lawyers ‘whose experience is deeply rooted in the space,’ Goodwin is able to assist life sciences sector clients across the spectrum of related issues, ranging from multi-billion dollar acquisitions, to securing FDA approval for groundbreaking drugs, and obtaining patent protection for their products. 2023 saw extensive hiring at the partner level, with the October 2023 arrivals of licensing specialist David Chen in Santa Monica from Ropes & Gray LLP and capital markets expert Adam Johnson from Latham & Watkins LLP in New York underscoring the arrival in Philadelphia of a 10-strong team from Troutman Pepper in February. Mitchell Bloom leads the team alongside Kingsley Taft, with both assisting clients in securing VC funding and with eventual IPOs, with the latter also handling licensing agreements and the structuring of joint ventures; both are based in Boston.  Also in Boston, Marishka DeToy and Robert Puopolo‘s practices center on capital markets transactions in the sector. The firm’s FDA regulatory experts are Steven Tjoe and Alexander Varond, both based in Washington DC and advising on medical devices and drug development processes.